Quadrant Capital Group LLC Has $8.31 Million Stock Holdings in Novo Nordisk A/S $NVO

Quadrant Capital Group LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 11.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 120,458 shares of the company’s stock after buying an additional 12,641 shares during the period. Quadrant Capital Group LLC’s holdings in Novo Nordisk A/S were worth $8,314,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of NVO. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S in the first quarter worth about $30,000. NewSquare Capital LLC boosted its position in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares in the last quarter. Disciplina Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the last quarter. Dagco Inc. acquired a new position in shares of Novo Nordisk A/S during the first quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $37,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent research reports. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $57.40.

Novo Nordisk A/S Stock Up 3.6%

Shares of NYSE NVO opened at $48.75 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $217.67 billion, a PE ratio of 13.39, a P/E/G ratio of 2.33 and a beta of 0.65. The company’s fifty day simple moving average is $53.32 and its 200 day simple moving average is $59.93. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.